RILEBBBU Trademark

Trademark Overview

On Thursday, July 25, 2019, a trademark application was filed for RILEBBBU with the United States Patent and Trademark Office. The USPTO has given the RILEBBBU trademark a serial number of 79270879. The federal status of this trademark filing is REGISTERED as of Tuesday, December 29, 2020. This trademark is owned by JCR Pharmaceuticals Co., Ltd.. The RILEBBBU trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the treatment of peripheral nervous system disorders; pharmaceutical preparations for the treatment of growth deficiencies; pharmaceutical preparations for the treatment of enzyme deficiencies; pharmaceutical preparations for the treatment of lysosomal storage diseases; pharmaceutical preparations for the treatment of Fabry disease, Gaucher disease, GM1 Gangliosidosis, GM2 Gangliosidosis, Krabbe disease, Niemann-Pick disease, Metachromatic leukodystrophy, Hurier syndrome, Hunter disease, Sanfilippo syndrome, Morquio syndrome, Sly syndrome, Pompe disease, Alfa-mannosidosis disease, Fucosidosis disease, and Neuronal ceroid lipofuscinosis
rilebbbu

General Information

Serial Number79270879
Word MarkRILEBBBU
Filing DateThursday, July 25, 2019
Status700 - REGISTERED
Status DateTuesday, December 29, 2020
Registration Number6230688
Registration DateTuesday, December 29, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 13, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the treatment of peripheral nervous system disorders; pharmaceutical preparations for the treatment of growth deficiencies; pharmaceutical preparations for the treatment of enzyme deficiencies; pharmaceutical preparations for the treatment of lysosomal storage diseases; pharmaceutical preparations for the treatment of Fabry disease, Gaucher disease, GM1 Gangliosidosis, GM2 Gangliosidosis, Krabbe disease, Niemann-Pick disease, Metachromatic leukodystrophy, Hurier syndrome, Hunter disease, Sanfilippo syndrome, Morquio syndrome, Sly syndrome, Pompe disease, Alfa-mannosidosis disease, Fucosidosis disease, and Neuronal ceroid lipofuscinosis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, November 8, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameJCR Pharmaceuticals Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP
Party NameJCR Pharmaceuticals Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP
Party NameJCR Pharmaceuticals Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events

Event DateEvent Description
Sunday, May 2, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, April 9, 2021FINAL DISPOSITION NOTICE SENT TO IB
Friday, April 9, 2021FINAL DISPOSITION PROCESSED
Monday, March 29, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, December 29, 2020REGISTERED-PRINCIPAL REGISTER
Sunday, October 18, 2020NOTIFICATION PROCESSED BY IB
Tuesday, October 13, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 13, 2020PUBLISHED FOR OPPOSITION
Wednesday, September 30, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, September 30, 2020NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, September 23, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 8, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, September 8, 2020EXAMINER'S AMENDMENT ENTERED
Tuesday, September 8, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, September 8, 2020EXAMINERS AMENDMENT E-MAILED
Tuesday, September 8, 2020EXAMINERS AMENDMENT -WRITTEN
Friday, September 4, 2020ASSIGNED TO EXAMINER
Wednesday, March 18, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, March 18, 2020FINAL REFUSAL E-MAILED
Wednesday, March 18, 2020FINAL REFUSAL WRITTEN
Friday, February 28, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 28, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 25, 2020ASSIGNED TO LIE
Thursday, February 20, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 20, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 20, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, February 20, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 20, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, February 20, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, December 21, 2019REFUSAL PROCESSED BY IB
Tuesday, December 3, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, December 2, 2019REFUSAL PROCESSED BY MPU
Wednesday, November 13, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, November 12, 2019NON-FINAL ACTION WRITTEN
Tuesday, November 12, 2019APPLICATION FILING RECEIPT MAILED
Friday, November 8, 2019ASSIGNED TO EXAMINER
Friday, November 8, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, October 31, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

rilebbbu disease pharmaceutical treatment preparations syndrome deficiencies gangliosidosis nervous system disorders